SCHEMBL803435

SCHEMBL803435

CC(C)(C)C(C)(C)F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14456621 0.80 — —
SCHEMBL9122069 0.78 — —
SCHEMBL20259523 0.78 — —
SCHEMBL6746524 0.78 — —
SCHEMBL1972855 0.78 — —
SCHEMBL5076821 0.75 — —
SCHEMBL125105 0.75 — —
SCHEMBL24869 0.75 — —
SCHEMBL553855 0.75 — —
SCHEMBL27314865 0.75 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399314-A1 CD73 INHIBITOR AND USE THEREOF Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) 2023-12-14 — — US disclosed
US-20230365525-A1 ANTIVIRAL COMPOUNDS ENANTA PHARMACEUTICALS, INC. 2023-11-16 — — US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 — — US disclosed
US-20230271973-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) 2023-08-31 — — US disclosed
US-20230271973-A1 BICYCLIC-HETEROCYCLE DERIVATIVES AND THEIR USES AS OREXIN-2 RECEPTOR AGONISTS CENTESSA PHARMACEUTICALS (OREXIA) LIMITED (GB) 2023-08-31 — — US disclosed
US-20230233526-A1 GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-07-27 — — US disclosed
US-20230233526-A1 GRANZYME B INHIBITOR COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SKIN BLISTERING AND/OR PEELING THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-07-27 — — US disclosed
US-11708351-B2 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders ACHILLION PHARMACEUTICALS, INC. (US) 2023-07-25 — — US disclosed
US-20230145305-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-11 — — US disclosed
US-20230145305-A1 COMPOUNDS USEFUL AS KINASE INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-11 — — US disclosed
US-20130261111-A1 TETRAHYDROPYRROLOTHIAZINE COMPOUNDS ELI LILLY AND COMPANY (US) 2013-10-03 — — US disclosed
US-20130189619-A1 RESIST COMPOSITION AND METHOD OF FORMING RESIST PATTERN TOKYO OHKA KOGYO CO., LTD. (JP) 2013-07-25 — — US disclosed
US-20130183269-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-07-18 — — US disclosed
US-8470819-B2 Benzimidazole and aza-benzimidazole carboxamides MERCK SHARP & DOHME CORP. (US) 2013-06-25 — — US disclosed
US-20130115194-A1 HEPATITIS C VIRUS INHIBITORS THERAVANCE BIOPHARMA R&D IP, LLC 2013-05-09 — — US disclosed
US-20120214762-A1 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR GENENTECH, INC. (US) 2012-08-23 — — US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 — — US disclosed
US-20110207750-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME LLC 2011-08-25 — — US disclosed
US-20110207750-A1 BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES MERCK SHARP & DOHME LLC 2011-08-25 — — US disclosed
US-7247757-B2 Method of producing a fluorine-containing vinyl ether compound FUJIFILM CORPORATION (JP) 2007-07-24 — — US disclosed
Send feedback